7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid | 934396-68-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid
• 英文别名: (4e)-7-Chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene)-1,2,3,4-tetrahydro-2-quinolinecarboxylic acid；(4E)-7-chloro-4-(2-oxo-1-phenylpyrrolidin-3-ylidene)-2,3-dihydro-1H-quinoline-2-carboxylic acid
• CAS: 934396-68-6
• 化学式: C₂₀H₁₇ClN₂O₃
• 分子量: 368.82
• InChiKey: XDKRVNKVAKCFGW-FOCLMDBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  26
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Tetrahydroquinoline derivatives as glycine antagonists
  申请人：——

  公开号：US20020052391A1

  公开（公告）日：2002-05-02

  1 Compounds of formula (I) or a salt, or metabolically labile ester thereof wherein R represents a group selected from halogen, alkyl, alkoxy, amino, alkylamino, dialkylamino, hydroxy, trifluoromethyl, trifluoromethoxy, nitro, cyano, SO 2 R 2 or COR 2 wherein R 2 represents hydroxy, methoxy, amino, alkylamino or dialkylamino; m is zero or an integer 1 or 2; R 1 represents a group (CH 2 ) n CN, —CH═CHR 3 , (CH 2 )nNHCOCH 2 R 4 or O(CH 2 )pNR 5 R 6 ; R 3 represents cyano or the group COR 7 ; R 4 represents alkoxy or a group NHCOR 8 ; R 5 and R 6 each represent independently hydrogen or alkyl, or R 5 and R 6 together with the nitrogen atom to which they are attached represent a heterocyclic group, or R 5 is hydrogen and R 6 is the group COR 9 ; R 7 represents an alkoxy, amino or hydroxyl group; R 8 represents a hydrogen atom or optionally substituted alkyl, alkoxy, aryl or heterocyclic group; R 9 is the group R 8 or the group NR 10 R 11 wherein R 10 represents hydrogen or alkyl group; R 11 represents optionally substituted alkyl, aryl, heterocyclic or cycloalkyl group; n is zero or an integer from 1 to 4; p is an integer from 2 to 4, processes for their preparation and to their use in medicine.

  化合物的公式(I)或其盐、代谢易变酯，其中R代表从卤素、烷基、烷氧基、氨基、烷基氨基、二烷基氨基、羟基、三氟甲基、三氟甲氧基、硝基、氰基、SO2R2或COR2中选择的基团，其中R2代表羟基、甲氧基、氨基、烷基氨基或二烷基氨基；m为零或整数1或2；R1代表(CH2)nCN、—CH═CHR3、( )nNHCO R4或O( )pNR5R6中的基团；R3代表氰基或基团COR7；R4代表烷氧基或基团NHCOR8；R5和R6各自独立地代表氢或烷基，或R5和R6与它们连接的氮原子一起代表杂环基团，或R5是氢而R6是基团COR9；R7代表烷氧基、氨基或羟基；R8代表氢原子或可选地取代的烷基、烷氧基、芳基或杂环基团；R9是基团R8或基团NR10R11，其中R10代表氢或烷基团；R11代表可选地取代的烷基、芳基、杂环或环烷基团；n为零或1到4的整数；p为2到4的整数，以及它们的制备过程和在医药上的应用。
• Heterocyclic derivatives
  申请人：——

  公开号：US20030008899A1

  公开（公告）日：2003-01-09

  The present invention relates to a novel salt of enantiomer A of 7-chloro-4-(2-oxo-1-phenyl-3-pyrrolidinylidene) 1,2,3,4-tetrahydro-2-quinoline carboxylic acid or a solvate thereof, to processes for its preparation, to pharmaceutical compositions containing it and to its use in therapy and in particularly its use as medicine for antagonising the effects of excitatory amino acids upon the NMDA receptor complex.

  本发明涉及 7-氯-4-(2-氧代-1-苯基-3-吡咯烷亚基)1,2,3,4-四氢-2-喹啉羧酸对映体 A 的一种新型盐或其溶液、其制备工艺、含有该对映体 A 的药物组合物及其在治疗中的用途，特别是作为药物用于拮抗兴奋性氨基酸对 NMDA 受体复合物的影响。
• TETRAHYDROQUINOLINE DERIVATIVES AS GLYCINE ANTAGONISTS
  申请人：GLAXO WELLCOME S.p.A.

  公开号：EP1086093A1

  公开（公告）日：2001-03-28
• MEGLUMINE SALT OF A SPECIFIC QUINOLINECARBOXYLIC ACID COMPOUND ACTIVE ON NMDA RECEPTORS
  申请人：GlaxoSmithKline S.p.A.

  公开号：EP1237886B1

  公开（公告）日：2006-04-19
• HETEROCYCLIC DERIVATIVES
  申请人：GlaxoSmithKline S.p.A.

  公开号：EP1237886A1

  公开（公告）日：2002-09-11